K-ras mutations in the bile of patients with primary sclerosing cholangitis

S Kubicka, F Kühnel, P Flemming, B Hain, N Kezmic, K L Rudolph, M Manns, P N Meier

Abstract

Background and aims—The development of cholangiocarcinoma (CCC) is a complication of primary sclerosing cholangitis (PSC). To date, no reliable factors have been described which can define those PSC patients at high risk for the development of CCC and the clinical diagnosis of CCC in PSC patients is difficult. Therefore, molecular markers of cholangiocarcinogenesis, such as K-ras mutations, may improve the early diagnosis of CCC or the timing of liver transplantation.

Methods—K-ras mutations were analysed by enriched polymerase chain reaction/restriction fragment length polymorphism in the bile fluid of 56 PSC patients and 20 patients with other cholestatic diseases. To assess the value of K-ras mutations as a risk factor for cholangiocarcinogenesis, patients were prospectively investigated over a mean period of 31.5 months.

Results—In contrast with the control group, 17 (30%) patients with PSC revealed K-ras mutations in bile fluid. The mean Mayo score was not significantly different between PSC patients with (mean score 0.70) and without (mean score 0.13; \( p=0.2 \)) K-ras mutations. In contrast with the group of PSC patients without K-ras mutations, four CCCs and two dysplasia were diagnosed in the group of patients with K-ras mutations during the follow up investigation (\( p<0.001 \)).

Conclusions—Our results indicate that K-ras mutations in bile fluid of PSC patients represent frequent early events during cholangiocarcinogenesis. However, most of the PSC patients with K-ras mutations remained tumour free after a long follow up investigation which is in agreement with the fact that these mutations are not specific for malignancy but may also occur in normal bile duct mucosa or in dysplasias. Therefore, analysis of K-ras mutations in bile should not be used for diagnosis of CCC in PSC patients. However, the results of our prospective follow up investigation indicate that K-ras mutations in bile fluid of PSC patients have to be considered as risk factors for the development of CCC which may have implications for the timing of liver transplantation.

(Gut 2001;48:403–408)

Keywords: K-ras mutations; cholangiocarcinogenesis; molecular diagnosis

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease of unknown aetiology, characterised by inflammation and progressive obliterative fibrosis of the intra- and extrahepatic bile ducts. \(^3,^4\) The clinical course of PSC is variable and unpredictable. The disease is often progressive and the majority of patients develop end stage liver disease. Large studies have shown an estimated median survival of approximately 12 years in symptomatic patients.\(^1,^2\) One commonly used treatment option with acceptable results for patients with end stage PSC is orthotopic liver transplantation (OLT). The one year survival rates of PSC patients after OLT have been reported to range from 71% to 88%.\(^2,^3\) Patients with PSC should be considered for liver transplantation if the estimated survival rate of the natural course of the disease is lower than after OLT. On the other hand, there is evidence that the most advanced stages of PSC appear to have an increased mortality and morbidity associated with OLT. Thus optimal timing of OLT, based on disease specific scores\(^1,^3,^11,^12\) or on the Child-Pugh classification,\(^13\) is important to improve outcome and decrease morbidity.

One complication of PSC is the development of biliary malignancies. The time from the initial diagnosis of PSC until recognition of cholangiocarcinoma ranges from 1 to 25 years.\(^4,^15\) The prognosis of PSC patients with cholangiocarcinoma is poor: the estimated median survival after diagnosis of the tumour is 5–7 months.\(^12,^16\) In particular, in patients who are considered for liver transplantation, the incidence of cholangiocarcinomas is high. Several studies revealed cholangiocarcinomas in 10–36% of PSC patients at the time of liver transplantation.\(^7,^9,^10,^18,^19\) In a retrospective study from our centre, cholangiocarcinomas were diagnosed in 10 of 48 (21%) explanted livers from PSC patients.\(^5\) In most of these studies the majority of tumours were clinically silent and were only detected by the pathologist in the explanted livers, thus highlighting the difficulties in the clinical diagnosis of cholangiocarcinomas in PSC patients.

However, the diagnosis of cholangiocarcinoma dramatically decreases the prognosis of PSC patients after OLT. In particular, tumour recurrence after liver transplantation is common.\(^1,^8,^20\) As liver function remains constant in

Abbreviations used in this paper: CCC, cholangiocarcinoma; OLT, orthotopic liver transplantation; PSC, primary sclerosing cholangitis; ERC, endoscopic retrograde cholangiography; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism.
many patients with PSC, the development of cholangiocarcinomas should also be considered as an indicator for OLT. But to date no reliable factors have been described which can define those PSC patients at high risk for the development of cholangiocellular carcinomas and the established prognostic disease scores are of limited use in predicting the risk of cholangiocarcinogenesis.

Some studies revealed a high incidence of bile duct dysplasia in patients with PSC and cholangiocarcinomas, consistent with the concept of multistage carcinogenesis. In colorectal cancer one frequent molecular event before the morphological occurrence of dysplasia is mutation of the K-ras oncogene. However, there is evidence that the incidence of K-ras mutations is high not only in biliary tract cancer but also in biliary tract dysplasia.

As K-ras codon 12 mutations represent excellent candidates for the molecular diagnosis of gene alterations in several body fluids, we hypothesised that similar mutations may also be detected in bile fluid of PSC patients and may be used for early tumour diagnosis or for establishing a risk factor for cholangiocarcinogenesis.

**Experimental procedures**

**PATIENTS AND BILE FLUID SAMPLES**

Fifty six patients with PSC and 20 patients with other benign cholestatic liver diseases (benign bile duct stenosis after OLT (n=11), choledocholithiasis (n=5), liver cirrhosis (n=3), Budd-Chiari syndrome (n=1)) were included in the study. The diagnosis of PSC was based on accepted criteria, including histological, biochemical, and radiological findings. Malignant tumour at the time of presentation of patients was excluded by ultrasound, tumour marker CA19-9, endoscopic retrograde cholangiography (ERC), and bile duct cytology.

Clinical variables were obtained by review of the patients’ charts at the Medizinische Hochschule Hannover. The onset of PSC was defined as the time of first presentation of abnormal liver function test consistent with a diagnosis of PSC.

Bile juice was obtained during ERC. Bile fluid (2 ml) was centrifuged at 12 000 rpm for 15 minutes. The pellet was washed twice with phosphate buffer saline and subsequently stored at −80°C.

The explanted livers of PSC patients undergoing OLT were intensively investigated by a pathologist. Tissue from the bile tract system with macroscopic evidence of hyperplasia or cholangiocarcinoma was fixed in formalin and embedded in paraffin wax.

**DNA EXTRACTION AND ENRICHED PCR-RFLP**

Tissue sections (5 µm) were cut from each of the tissue blocks. Adjacent sections were stained with haematoxylin-eosin to confirm the histological diagnosis. Genomic DNA from the tissue specimen or from the bile pellets was extracted using the QIAamp tissue kit (Qiagen Inc. Valencia, USA) according to the manufacturer’s instruction. To avoid DNA contamination, each of the samples was processed independently.

Enriched polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed as described previously with minor modifications. Amplification with Taq polymerase was performed in 100 µl reaction mixtures containing 2 units of polymerase, 100 pmol of each primer, 2mM Mg³⁺, 60 mM KCl, 10 mM Tris-HCl (pH 8.8), and dNTP (dATP, dCTP, dGTP, dTTP) at 200 µmol. The reaction mixture was overlaid with 75 µl of mineral oil and subjected to amplification (Landgraf). Each cycle consisted of 94°C for one minute, 55°C for 90 seconds, and 72°C for 90 seconds. The first PCR comprised 20 cycles; 5 µl of the PCR product were digested with 2 units of BstNI (New England Biolabs Inc., Beverly, USA) in a volume of 20 µl for 12 hours.Wild type fragments cleave to yield 114 base pairs whereas mutant fragments yield 143 base pairs. 1/1000 of the first digest was used as a template for the second PCR of 30 cycles. During this step the 143 base pair fragments with the ras codon 12 mutations were selectively amplified. The sequences of the primers in the first PCR were: (A) 5’-ACTGAAATAAAGCTGAGTGTCTCTTGTTGAGCTT-3’; (B) 5’-CTAAGAATTGCTGGACC-3’. In the second PCR, instead of primer (B), primer (C) was used: (C) 5’-GCATATTAAACAGATTAT-3’.

A second BstNI digest with 20 µl of the second PCR product was performed. Subsequently, the digest was separated by electrophoresis on a 2% agarose gel.

**DNA SEQUENCING**

If a ras codon 12 mutation specific band was noted in a sample by agarose gel electrophoresis, 1 µl of the second PCR product was used for subcloning the DNA fragment in a plasmid using the TA cloning kit (Invitrogen, Carlsbad, USA) according to the manufacturer’s instructions. DNA sequencing of the K-ras genes in plasmids was performed with primer C using the sequenase 2.0 kit (Amersham Life Science, Cleveland, Ohio, USA). To rule out PCR generated artefacts, all K-ras mutations were confirmed by repeating PCR-RFLP and DNA sequencing.

**MAYO NATURAL HISTORY MODEL FOR PRIMARY SCLEROSING CHOLANGITIS**

The clinical data for calculation of the Mayo risk scores were obtained at the time of ERC where bile fluid was collected for molecular analysis. The clinical data for calculation of the Mayo risk scores were confirmed by repeating PCR-RFLP and DNA sequencing.

**STATISTICAL ANALYSIS**

The χ² test and Fisher’s exact test were used to compare differences between proportions. A difference with a p value equal to or less than 0.05 was considered significant. Fisher’s exact
K-ras mutations and primary sclerosing cholangitis

Table 1 Incidences of K-ras mutations in patients with primary sclerosing cholangitis (PSC) with or without ulcerative colitis (UC)

<table>
<thead>
<tr>
<th></th>
<th>PSC</th>
<th>PSC and UC</th>
<th>PSC without UC</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSC with K-ras mutations (n=17)</td>
<td>35%</td>
<td>27%</td>
<td>0%</td>
<td>30%</td>
</tr>
<tr>
<td>PSC without K-ras mutations (n=39)</td>
<td>30%</td>
<td>35%</td>
<td>0%</td>
<td>30%</td>
</tr>
</tbody>
</table>

Table 2 Scores for the Mayo natural history model in patients with primary sclerosing cholangitis (PSC) with regard to K-ras mutations

<table>
<thead>
<tr>
<th></th>
<th>Mean value</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSC with K-ras mutations (n=15)</td>
<td>0.70</td>
<td>-1.2–3.92</td>
</tr>
<tr>
<td>PSC without K-ras mutations (n=29)</td>
<td>0.13</td>
<td>-1.6–4.03</td>
</tr>
</tbody>
</table>

Table 3 Prognostic significance of K-ras mutations for the development of bile duct dysplasias and cholangiocarcinomas (CCC)

<table>
<thead>
<tr>
<th></th>
<th>Mean follow up period (months)</th>
<th>CCC</th>
<th>Dysplasia</th>
<th>Dysplasia + CCC</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSC with K-ras mutations (n=17)</td>
<td>34.6</td>
<td>4</td>
<td>2</td>
<td>6</td>
</tr>
<tr>
<td>PSC without K-ras mutations (n=39)</td>
<td>30.2</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Results

INCIDENCE OF K-ras CODON 12 MUTATIONS IN BILE JUICE OF PATIENTS WITH PRIMARY SCLEROSING CHolangitis

As K-ras codon 12 mutations can be detected in several body fluids by a sensitive PCR-RFLP, we hypothesised that molecular analysis of K-ras mutations in the bile of PSC patients may be used for the early diagnosis of cholangiocarcinomas in these patients. Thus we prospectively investigated the bile fluid of PSC patients, obtained during retrograde cholangiography, for K-ras mutations at codon 12.

Fifty six patients with PSC without clinical evidence of biliary tract malignancies were included in the study. The incidence of ulcerative colitis and K-ras mutations in the bile of patients is shown in table 1.

Mutation patterns included GGT to GTT transversion (n=7), GGT to GAT transition (n=6), GGT to AGT transition (n=3), and GGT to GCT (n=1) transversion. The mutation spectrum resembled the base substitutions of the K-ras gene described in cholangiocarcinomas by other investigations. There was no significant difference in the incidence of K-ras mutations between PSC patients with or without ulcerative colitis (table 1). As a control, the bile juice of 20 patients with cholestatic diseases without evidence of PSC or biliary tract malignancy were analysed for K-ras mutations. In contrast with the bile juice from PSC patients, no K-ras codon 12 mutations were observed (table 1). As 30% of PSC patients without clinical evidence of cholangiocarcinomas showed K-ras mutations, we hypothesised that these gene alterations do not reflect undetectable cholangiocarcinomas but are frequent early molecular events in bile duct mucosa of PSC patients which may promote the development of cholangiocarcinomas.

Several natural history models have been described to assess the prognosis of PSC patients to improve the timing of liver transplantation but none of these models contained factors to assess the risk of carcinogenesis. Thus we investigated the correlation between the established Mayo natural history model score of PSC and the occurrence of K-ras mutations. Reliable clinical data for this risk score, obtained at the time of ERC, were available for 44 of 56 PSC patients. Although there was no significant difference (p=0.2) in the disease specific score between patients with or without K-ras mutations in bile, the incidence of K-ras gene alterations tended to be higher in patients with advanced PSC (table 2).

FOLLOW UP STUDY OF PATIENTS WITH PSC AND K-ras GENE MUTATIONS IN BILE JUICE

K-ras mutations in the bile of PSC patients may reflect either molecular events in normal mucosa, premalignant bile duct lesions, or early stages of cholangiocarcinomas. The high incidence of these gene alterations in PSC patients without clinical evidence of cholangiocarcinomas indicates that K-ras mutations occur often in normal mucosa or in premalignant bile duct lesions and have to be considered as a risk factor for tumour development. To assess the role of K-ras mutations in bile as a risk factor for PSC patients, we performed a follow up investigation. During the follow up periods all patients were systematically investigated with ultrasound and assessment of the tumour marker CA19-9 every three months. In cases with evidence of tumour growth at ultrasound or CA19-9, a CT scan and ERC with bile duct cytology were also performed.

In the group of patients without K-ras mutations no cholangiocarcinoma was clinically diagnosed during the follow up period (mean follow up duration 30.2 months; range 6–54). During follow up, 15 PSC patients without K-ras mutations underwent liver transplantation. The explanted livers were investigated by a pathologist. The histology of the explanted livers revealed only the typical inflammatory bile ducts of PSC. There was no evidence of bile duct dysplasia or malignancy. Also, PSC patients with K-ras mutations in bile fluid were prospectively investigated. The mean follow up period was 34.6 months (range 1–44). In this group of patients, two cholangiocarcinomas were clinically diagnosed by imaging techniques on ultrasound and CT scan during the follow up period. The malignancies were confirmed by cytology. The intervals between detection of K-ras mutations in bile and clinical diagnosis of cholangiocarcinomas were 14 months and 36 months, respectively (tables 3, 4).

During follow up, four patients with K-ras mutations in bile fluid underwent OLT. In two cases the explanted livers revealed dysplasias of large bile ducts and in two other cases inciden-
tal cholangiocarcinomas were detected by the pathologist (fig 1). In one of these patients the interval between molecular analysis of a K-ras mutation in bile and the diagnosis of cholangiocarcinoma was only one month (table 4). Therefore, it is likely that the malignant tumour was already present at the time of ERC where bile fluid was collected. Although this carcinoma was only incidentally detected during liver transplantation, the tumour was at an advanced stage with local peritoneal metastases.

Tissues of two cholangiocarcinomas and two dysplasias were available for molecular analysis of K-ras mutations after OLT. Three of the K-ras mutations initially found in bile fluid of patients with primary sclerosing cholangitis at the time of inclusion in the study (left) were confirmed in the corresponding tissues of two cholangiocarcinomas and one dysplasia after OLT (right).

**Table 4** Characteristics of patients with primary sclerosing cholangitis (PSC) who developed cholangiocarcinoma or bile duct dysplasia during the follow up investigation

<table>
<thead>
<tr>
<th>Age</th>
<th>First PSC diagnosis</th>
<th>K-ras mutation</th>
<th>Follow up investigation</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>45 y</td>
<td>1974</td>
<td>7/97</td>
<td>9/98 Carcinoma</td>
<td>Diagnosis of cholangiocarcinoma by CT scan and cytology. Normal CA19-9; T4N1M0.</td>
</tr>
<tr>
<td>36 y</td>
<td>1996</td>
<td>1/96</td>
<td>1/99 Carcinoma</td>
<td>Diagnosis of cholangiocarcinoma by CT scan and cytology. Normal CA19-9; T4N1M0.</td>
</tr>
<tr>
<td>34 y</td>
<td>1997</td>
<td>7/96</td>
<td>8/97 Carcinoma</td>
<td>Incidental diagnosis of cholangiocarcinoma during OLT. Normal CA19-9; T1N0M1.</td>
</tr>
<tr>
<td>34 y</td>
<td>1989</td>
<td>4/96</td>
<td>7/97 Dysplasia</td>
<td>Diagnosis of bile duct dysplasia in explanted liver (OLT 7/97).</td>
</tr>
</tbody>
</table>

CT, computed tomography; OLT, orthotopic liver transplantation.

**Discussion**

One known risk factor for the development of biliary tract cancer is PSC. Although many biliary tract carcinomas complicating PSC can be detected by imaging methods such as computed tomography, cholangiography, ultrasonography, and magnetic resonance, there is an urgent need for further tools to improve the early diagnosis of cholangiocarcinomas in patients with PSC. The serum tumour markers CA19-9 and CEA may be helpful for detection of a cholangiocarcinoma in a patient with PSC. In addition, FDG-PET may have potential in the diagnosis of biliary carcinomas in these patients and may facilitate the decision of whether or not to accept a PSC patient on a waiting list for liver transplantation. However, the early diagnosis of biliary cancer in PSC patients remains difficult. Hence one aim of our study was to evaluate molecular analysis of K-ras mutations as a new method for the early diagnosis of cholangiocarcinomas in PSC patients. In our study, K-ras mutations were frequently observed in bile fluid of PSC patients. However, most patients with K-ras mutations in bile remained cancer free for more than 12 months after analysis of the K-ras gene mutation. As cholangiocarcinomas are very fast growing tumours with a poor prognosis, it is obvious that the sources of most of the K-ras mutations were not malignant tumours. Moreover, our study confirmed earlier observations that K-ras mutations can also be found in bile duct dysplasias, which are considered as premalignant lesions in PSC patients. These results indicate that K-ras mutations in PSC patients often represent early molecular events in normal mucosa or in dysplasias and are not specific signs of malignancy. Therefore, molecular analysis of K-ras mutations in the bile of PSC patients would seem to be of limited use for early diagnosis of cholangiocarcinomas.

As a consequence of these results we considered that the molecular diagnosis of K-ras mutations may be useful for establishing a molecular risk factor for carcinogenesis in PSC patients. In fact, our prospective investigation demonstrated that significantly more cholangiocarcinomas or dysplasias were diagnosed in the group of PSC patients with K-ras mutations in bile fluid during the mean follow up period of 31.5 months (p=0.002). Recently, a prospective study in patients with chronic pancreatitis investigated whether K-ras mutations...
K-ras mutations and primary sclerosing cholangitis

in duodenal fluid could identify high risk patients for the development of pancreatic carcinoma. Contrary to our results, K-ras gene mutations in this study were not directly relevant to the development of pancreatic neoplasm. However, the risk of pancreatic cancer in patients with chronic pancreatitis is much lower than the risk of biliary cancer in PSC patients, which may explain the different results obtained in our study regarding the prognostic value of K-ras mutations. To demonstrate the prognostic relevance of K-ras mutations in the bile of patients with chronic pancreatitis, a longer follow up study may be necessary.

In three cases K-ras mutations of bile fluid were confirmed in tissues with cholangiocarcinomas and dysplasia after liver transplantation. However, we failed to confirm all mutations found in bile in the corresponding tissues. This may be explained by methodical limitations, or may reflect the multicentric development of cholangiocarcinomas in PSC patients.

In three of the four cholangiocarcinomas, the interval between molecular diagnosis of a K-ras mutation in bile and diagnosis of cholangiocarcinoma was longer than 11 months. Considering the poor prognosis of cholangiocarcinomas, detection of K-ras gene alterations in bile fluid in these patients either reflected a precancerous lesion (dysplasia) or a very early tumour stage. Although several studies demonstrated that incidental cholangiocarcinomas do not affect patient survival after liver transplantation, the prognosis of these patients is difficult to estimate and depends in particular on tumour stage. However, it seems reasonable to assume that liver transplantation performed at the time of diagnosis of the K-ras mutations in bile fluid would have improved the prognosis of these three patients. But it remains speculative whether the prognosis of all PSC patients with K-ras mutations in bile fluid could be improved if they underwent transplantation earlier. Although our study indicates that K-ras mutations in bile fluid of PSC patients are poor prognostic factors for the development of dysplasia and/or cholangiocarcinomas, the optimal timing of liver transplantation of these patients should be investigated by further prospective studies.

Our study demonstrated that mutation of codon 12 of K-ras is a frequent early event in the carcinogenesis of PSC associated cholangiocarcinomas. K-ras mutations at codon 12 are not specific for malignant bile duct tumours in PSC patients and may often appear before the occurrence of morphological signs of dysplasia or malignancy. As a consequence, molecular analysis of K-ras mutations in bile fluid, obtained by ERC, seems of little use for early diagnosis of cholangiocarcinomas in PSC patients. However, a significant number of PSC patients with K-ras mutations developed cholangiocarcinomas or dysplasias during a follow up investigation in contrast with a group of patients without K-ras mutations. Thus K-ras codon 12 mutation in bile fluid appears to be a prognostic factor for PSC patients which may be important for the timing of liver transplantation.

We thank Monique Hörning for secretarial assistance. The research was supported by a grant from the Deutsche Forschungsgemeinschaft Sonderforschungsbereich 265, project CAA.

30 Castells A, Puig P, Mora J, et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic...
K-ras mutations in the bile of patients with primary sclerosing cholangitis

S Kubicka, F Kühnel, P Flemming, B Hain, N Kezmic, K L Rudolph, M Manns and P N Meier

Gut 2001 48: 403-408
doi: 10.1136/gut.48.3.403

Updated information and services can be found at:
http://gut.bmj.com/content/48/3/403

These include:

References
This article cites 40 articles, 8 of which you can access for free at:
http://gut.bmj.com/content/48/3/403#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Pancreas and biliary tract (1949)
Hepatic cancer (474)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/